ABSTRACT
Extracorporeal photochemotherapy (ECP) has been shown to be an effective therapy for patients with acute and chronic graft-vs-host disease (GVHD) following allogeneic bone marrow transplantation, but its biological mechanism is not understood. We reported that clinical response to ECP was associated not only with normalization of skewed CD4/CD8 ratios, but also with an increase in CD3 only.
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INTRODUCTION
Acute and chronic graft-versus-host disease (aGVHD and cGVHD) represent a major cause of morbidity and mortality following allogeneic bone marrow transplantation (BMT). 1 The incidence of aGVHD ranges from 20-50% and is dependent on factors related to the graft as well as the effects of conditioning regimens on host tissue. Chronic GVHD affects 30-50% of successfully engrafted patients and is thought to be related to ongoing alloreactivity against minor HLA-antigen mismatch between the donor and recipient. 
MATERIALS and METHODS

Reagents
Tetanus toxoid (TT) was provided by Massachusetts public health biological laboratories 
Patients
Patients had a diagnosis of extensive cGVHD, refractory to standard therapy (at least 4 weeks of prednisone 1mg/kg or equivalent), with therapeutic levels of cyclosporin A (CSA). All patients had progressive or symptomatic, non-responsive cGVHD. Five patients had failed mycophenolic acid on an institutional Phase II study, and two failed tacrolimus. All patients had extensive sclerodermatous skin changes. All patients had only.
For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From ECOG performance status < 3. Patients with history of photosensitive disease, psoralen allergy, or active uncontrolled infection were ineligible. All patients signed informed consent conforming to an institutional review board-approved protocol. ECP was performed on 2 consecutive days every 2 weeks as previously described. Toxicity and response was assessed on day 0 and at the beginning of each 2-week treatment cycle using the NCI common toxicity criteria. Patients continued their immunosuppressive agents, which were adjusted for the activity of their cGVHD.
Generation of dendritic cells from monocytes
Fresh peripheral blood mononuclear cells (PBMC) from patients were isolated by ficollhypaque (Amersham-Pharmacia Biotech, Upsala, Sweden) gradient centrifugation. Nonadherent cells were removed by incubation of cells 16 h on culture flasks in complete medium (RPMI-1640 medium including 10% human AB serum, 50µg/ml glutathione, 50µg/ml streptomycin and 50µg/ml penicillin) at 5% CO 2 days. DCs were pulsed once with TT concentration at 0.01Lf/ml on day 3. Ag was removed washing the cells and renewing the supplemented medium. The maturationinducing agent TNF was added to the supplemented culture medium at day 4 (20ng/ml) and at day 6 (10ng/ml). DCs were stimulated with PMA (10ng/ml) at day 6 for 2 days.
Cells were collected at the end of the culture (day 8) by incubating with PBS containing 0.2mmol/L EDTA for 5 minutes.
Flow cytometry
Cell staining was performed on 1x10 5 Cells were washed twice with PBS supplemented with 0.5%BSA and 2mM EDTA.
Cytokine secreted T cell subsets were detected by flow cytometry using a 388nm argon laser. Datas were analysed with student T-test and shown as mean with standard error. P values were detected as 0.05.
RESULTS
Ten consecutive patients undergoing ECP for cGVHD after allogeneic bone marrow transplantation were studied. As we previously reported, 9 of 10 responded to treatment with improvement in sclerodermatous skin changes and in oral, musculoskeletal, hepatic, and lung involvement . Patients received two consecutive days of ECP every 2 weeks.
Lymphocyte and dendritic cell subsets and functional analysis was performed prior to initiation and at the completion of day 2 (post-photopheresis) of each photopheresis cycle.
Patients were treated for a minimum of 6 months and until response plateau. Peripheral only.
For Similar results were obtained at 6 and 12 months of therapy, and the overall change in DC populations during treatment was consistent among patients, as shown in Table 1 . Table 3 . Similar proportional changes in cytokine profiles were seen before and after each cycle of ECP and were consistent at initiation of therapy and at 6 and 12 months or last cycle of ECP, as shown in Figure 3 . 
DISCUSSION
The pathogenesis of cGVHD is controversial and may be related either to an extension of the acute alloreactivity seen in aGVHD or a manifestation of dysfunctional immune reconstitution with generation of tissue auto-reactive T-cell clones and dysregulation of CD4 + CD25 + immune modulating T-cells. In murine GVHD models, donor CD4-enriched cells of TH2 phenotype have been shown to prevent GVHD without affecting engraftment, suggesting that they play a role in downregulating the TH1 response. 12 Similarly, in chronic GVHD, upregulation of TH1 cytokines IFN and IL-12 in peripheral blood mononuclear cells implicates in part a TH1-driven mechanism. We demonstrate here that ECP alters host (autologous) lymphocyte proliferation in MLR by modulating DC antigen presentation and differentiation of DC subtypes, favoring decrease in DC1 and increase in DC2 cells (Figure 4) . The CD123 + lymphoid DC1 dendritic cells produce large amounts of IFN . 15 Although these cells might also process only.
For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From and present antigen, they are postulated to enter lymph nodes through the high endothelial venule. 16 Previous studies with low dose cutaneous ultraviolet B radiation in patients with Interestingly, umbilical cord blood, another source of allogeneic stem cells for transplantation associated with relatively low incidence of acute GVHD, contains DC2
but not DC1 cells. 
